

UNIVERSITY OF ILLINOIS
AT URBANA - CHAMPAIGN



Veterinary Teaching Hospital
College of Veterinary Medicine
1008 West Hazelwood Drive
Urbana, IL 61802

Funded Study: Treatment of Canine Appendicular Osteosarcoma

University of Illinois Cancer Care Clinic and Comparative Oncology Research Laboratory

Study Title

Evaluation of Subcutaneous Injection of CPG for Dogs with Osteosarcoma

Purpose of the Study

The immune system plays an important role in cancer and contributes to the development, progression, and metastasis of cancer as well as play a role in fighting cancer. This clinical trial is investigating an oligomer (CPG) that is injected under the skin at the site of the osteosarcoma tumor with the intent of stimulating the cells of the immune system that can fight cancer and prevent its spread to other parts of the body. To date, this has been well tolerated at dogs in other studies.

Inclusion Criteria

- Dogs with histologically or cytologically confirmed appendicular osteosarcoma (Excluding lesions of the femur)
- Dogs must be at least 25 kilograms in weight
- Dogs cannot have been treated with chemotherapy, radiation therapy, or bisphosphonates
- Dogs cannot have been on NSAIDs for at least 7 days prior to starting the trial

Eligibility Diagnostics

Prior to study entry, pet owners will be financially responsible and required to have the following diagnostics performed on their pet:

- 1) Screening blood work and urinalysis
- 2) Cytologic or histologic confirmation of appendicular osteosarcoma

Treatment

- All dogs enrolled will receive 1 injection of CPG subcutaneous over the tumor
- Blood work and lymph node aspirates will be collected on Day 1, Day 2, and Day 7

Compensation

The study will pay for the cost of the CPG injection, for hospitalization (if needed overnight between Day 1 and Day 2), and the cost of blood work and recheck fees for each of the visits. Pet owners will be receive a \$250 credit on their account at the hospital to be used for any future treatments performed here. They will also receive three Zometa treatments (a bone strengthening agent used in osteosarcoma dogs). The Zometa compensation will only be for the cost of the drug, and owners will be responsible for appointment fees, blood work and administration of the drug. Pet owners will be responsible for initial diagnostics performed to confirm study eligibility (see Eligibility Diagnostics ~\$400).

Contact Information

Please feel free to call Rebecca Kameron at (217) 300-6453. Referring veterinarian and client calls are welcome.